Dyadic International, Inc. Pricing Details
Dyadic International, Inc. (NASDAQ: DYAI), a noted name in biotechnology, recently revealed that it has set the price for its public offering of 6,052,000 shares of common stock. This strategic move underscores the company's ongoing commitment to advancing its innovative gene expression platforms, which facilitate the production of specialized proteins across various industries including life sciences, food and nutrition, and industrial sectors.
Role of Craig-Hallum Capital Group
The esteemed Craig-Hallum Capital Group LLC steps in as the sole managing underwriter for this comprehensive offering. This partnership is fundamental to ensuring the offering's success while paving the way for Dyadic to further its mission in the biotechnology landscape.
Usage of Proceeds from the Offering
Dyadic intends to channel the net proceeds from this public offering towards enhancing its working capital, along with general corporate purposes. The company aims to support various projects related to product development, sales enhancements, and marketing efforts. This financial influx is crucial for fueling innovation and expanding Dyadic's reach within its markets.
Details of the Securities Offering
The shares being offered are part of an effective shelf registration statement filed with the Securities and Exchange Commission (SEC). This statement, declared effective, allows Dyadic to streamline its offering processes and increase investment activities promptly. Investors can access the preliminary prospectus supplement related to this offering, which includes comprehensive details regarding the securities and the offering process.
About Dyadic Applied BioSolutions
Dyadic Applied BioSolutions stands out in the biotechnology arena for its avant-garde methodologies that enable the production of high-quality recombinant proteins. These proteins are not only pivotal for the company's growth but are also integral to enhancing production processes across its partnered programs in sectors like life sciences and food technology. Through its proprietary C1 and Dapibus™ expression systems, Dyadic ensures cost-effective and scalable manufacturing, fostering sustainability and efficiency in the production of high-value proteins.
Investor Communications
If you're interested in learning more about Dyadic or have queries regarding this offering, you can contact Dyadic's Chief Financial Officer, Ping W. Rawson. The company encourages open communication with potential and current investors, which is critical for maintaining transparent business practices.
Contact Information
Dyadic Applied BioSolutions
Ping W. Rawson
Chief Financial Officer
Phone: (561) 743-8333
Email: ir@dyadic.com
Frequently Asked Questions
What is the primary purpose of the shares being offered?
The shares are being offered to enhance working capital and fund general corporate purposes, focusing on product development and marketing.
Who is the underwriter for this public offering?
The sole managing underwriter for the offering is Craig-Hallum Capital Group LLC.
How many shares are being offered in this public offering?
Dyadic International is offering a total of 6,052,000 shares of common stock.
What financial benefits does Dyadic anticipate from this offering?
The company expects to bolster its working capital, allowing for expansion in its product development and marketing strategies.
Where can investors find more information about the offering?
The preliminary prospectus supplement can be accessed via the SEC's website, providing detailed insights into the offering process.
